1 edition of Novel therapeutic targets for antiarrhythmic drugs found in the catalog.
Novel therapeutic targets for antiarrhythmic drugs
George Edward Billman
Includes bibliographical references and indexes.
|Statement||edited by George Edward Billman|
|LC Classifications||RM347 .N68 2010|
|The Physical Object|
|Pagination||xxiv, 578 p.,  p. of plates :|
|Number of Pages||578|
|LC Control Number||2009020796|
Novel Therapeutic Targets for Antiarrhythmic Drugs by George Edward Billman Solutions Manual for Perspectives on Structure and Mechanism in Organic Chemistry, 2nd Edition. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs). relations.
Analysis of the FDA’s Electronic Orange Book. The FDA Approved Drug Products with Therapeutic Equivalence Evaluations 26 th Edition Electronic Orange Book (EOB) 4 li approved prescription drugs (RX) with therapeutic equivalence evaluations, approved over-the-counter (OTC) drugs, and a list, containing approved products that have been by: New Antiarrhythmic Drugs. Amiodarone 7,8 has served as a model compound for the development of new antiarrhythmic drugs, which are often analogues of amiodarone. Amiodarone is more effective than other clinically available antiarrhythmic drugs, and its proarrhythmic potential is relatively low. 9 Therefore, it is the only antiarrhythmic agent that is recommended for use in patients with overt.
Atrial fibrillation is the most common clinically significant cardiac arrhythmia, increasing the risk of stroke, heart failure and morbidity and mortality. Current therapies, including rate control and rhythm control by antiarrhythmic drugs or ablation therapy, are moderately effective but far from optimal. Gene therapy has the potential to become an attractive alternative to currently Cited by: 7. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. The present review provides contemporary data gathered on all drugs effective in the therapy of BrS, and on ineffective or contraindicated antiarrhythmic by: 7.
Sonnets of the English Renaissance
communicative approach to language teaching and its implications for syllabus design in Libya.
How to control and use photographic lighting
Mad Millennium Joke Book
GANGA tere desh mein
British standard graphical symbols for use in diagrams for hydraulic and pneumatic systems
Ghostly Enchantment (Harper Monogram)
Trashing nuclear power
Cock-a-doodle-do, or, Harlequin Prince Chanticleer, and the princess of the Golden Valley
healing of nations
Interlibrary loan policies of Pacific Northwest libraries, 1937.
Bench-scale studies of the Fischer-Tropsch systhesis over iron, nickel, and nickel-cobalt catalysts (Japan)
directory of Canadian northern field research stations, 1986
Novel therapeutic targets for antiarrhythmic drugs book a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments for cardiac arrhythmias alongside comprehensive presentations of basic cardiac physiology and pharmacology.
Written by leading experts in their research areas, this invaluable resource offers both practitioners and Cited by: 3. Offering an unparalleled look at the current state and future direction of cardiac arrhythmia treatment, Novel Therapeutic Targets for Antiarrhythmic Drugs provides an important resource to advanced students, working researchers, and busy professionals alike.
The consequence of poorly focused treatment is unintended toxicities, including proarrhythmia. And nobody wants to develop or approve unsafe drugs. Clearly, there is a need for a more targeted approach to the development and deployment of antiarrhythmic drugs, and this book is an admirable attempt to find a Author: Peter R.
Kowey. Request PDF | Novel Therapeutic Targets for Antiarrhythmic Drugs | Introduction Effects of K+ Channel Blockade on APD and Arrhythmogenesis Conclusions/Future Directions References | Find, read and.
How to Cite. Carnes, C. () Antiarrhythmic Drug Classification, in Novel Therapeutic Targets for Antiarrhythmic Drugs (ed G. Billman), John Wiley & Sons, Inc. / Hugh Clements-Jewery and Michael Curtis --Cardiac sarcolemmal ATP-sensitive potassium channel antagonists: a class of drugs that may selectively target the ischemic myocardium / George E.
Billman --Mitochondrial origin of ischemia-reperfusion arrhythmias / Brian O'Rourke --Cardiac gap junctions: a new target for antiarrhythmic drugs: gap.
Novel Therapeutic Targets for Antiarrhythmic Drugs by George Edward Billman (). Get free shipping on Novel Therapeutic Targets for Antiarrhythmic Drugs ISBN from TextbookRush at a great price and get free shipping on orders over $35.
Get this from a library. Novel therapeutic targets for anti-arrhythmic drugs. [George Edward Billman;] -- Profiles potential treatment approaches for cardiac arrhythmias. Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial.
Download Citation | Novel Therapeutic Targets for Antiarrhythmic Drugs | George Edward Billman ed. pages. Hoboken, NJ, USA: John Wiley and Sons, Inc, $ ISBN: Section Three describes several novel pharmacological targets for antiarrhythmic drugs, including both ion channel and non-ion channel targets.
Section Four describes promising non-pharmacological antiarrhythmic interventions including selective cardiac neural disruption or nerve stimulation, aerobic exercise training, and diet (omega-3 fatty Author: George Edward Billman.
ion channels as therapeutic targets Download ion channels as therapeutic targets or read online books in PDF, EPUB, Tuebl, and Mobi Format. Click Download or Read Online button to get ion channels as therapeutic targets book now.
This site is like a library, Use. Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments for cardiac arrhythmias alongside comprehensive presentations of basic cardiac physiology and pharmacology. Written by leading experts in their research areas, this invaluable resource offers both practitioners and researchers a one-stop guide that brings together.
A fact from Novel Therapeutic Targets for Antiarrhythmic Drugs appeared on Wikipedia's Main Page in the Did you know. column on 20 January (check views).The text of the entry was as follows: "Did you know that Novel Therapeutic Targets for Antiarrhythmic Drugs was described as an "illuminating and far reaching" work on arrhythmia treatment?"; A record of the entry may be seen at.
a framework for a modernized classification of established antiarrhythmic drugs based on their pharmacological targets. The revised classification allows for the existence of multiple drug targets/actions and for adverse, sometimes actually proarrhythmic, effects. The new scheme also aids classification of novel drugs under investigation.
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
Many attempts have been made to classify antiarrhythmic agents. The problem arises from the fact that many of the. The success of mechanism-based drug discovery depends on the definition of the drug target, but targets are often poorly defined in the literature.
Here, Overington and colleagues present a Cited by: Thus, novel drug targets have been characterised and are currently being tested in experimental and clinical studies.
Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management. VOLUME: 5 The constitutively active form of this current is increased in human AF and pharmacological inhibition might be of therapeutic value.
Certain. Syntheses of all presented drugs are described in our previous book . In the last decade no novel antiarrhythmics entered the pharmaceutical market, and none is presented in the list of Top Drugs by sales for the s.
Recent advances and progress in antiarrhythmic drugs have been critically reviewed [24. Frank J. Dowd, in Pharmacology and Therapeutics for Dentistry (Seventh Edition), Drug Interactions. Antiarrhythmic drugs can participate in a wide variety of drug interactions.
Because the margin of safety with these drugs as a group is narrow, clinically significant interactions may develop whenever the activity or plasma concentration of an antiarrhythmic agent is altered.
The present paper reviews the main novel results on atrial tachycardia-induced electrical, structural and contractile remodeling focusing on the underlying pathophysiological and molecular basis of their occurrence. Special attention is paid to novel strategies and targets with Cited by: 8.Glaaser I., Clancy C.
() Cardiac Na+ Channels as Therapeutic Targets for Antiarrhythmic Agents. In: Basis and Treatment of Cardiac Arrhythmias. Handbook of Experimental Pharmacology, vol Cited by: Author(s): Billman,George Edward, Title(s): Novel therapeutic targets for antiarrhythmic drugs/ edited by George Edward Billman.
Country of Publication: United States Publisher: Hoboken, N.J.: John Wiley & Sons, c